Cardiff Oncology, Inc. financial data

Symbol
CRDF on Nasdaq
Location
San Diego, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 06 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 539% % -5.12%
Debt-to-equity 23% % 2.76%
Return On Equity -77% % -4.38%
Return On Assets -63% % -3.86%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 67,360,564 shares 31.7%
Common Stock, Shares, Outstanding 67,095,000 shares 37.7%
Entity Public Float $99,095,121 USD 54%
Common Stock, Value, Issued $7,000 USD 40%
Weighted Average Number of Shares Outstanding, Basic 66,879,000 shares 42.7%
Weighted Average Number of Shares Outstanding, Diluted 66,879,000 shares 42.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $500,000 USD -27.4%
Operating Income (Loss) $-53,705,000 USD -15.7%
Nonoperating Income (Expense) $3,283,000 USD -4.29%
Net Income (Loss) Attributable to Parent $-50,422,000 USD -17.3%
Earnings Per Share, Basic 0 USD/shares 14.9%
Earnings Per Share, Diluted 0 USD/shares 14.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $10,135,000 USD -22.3%
Cash, Cash Equivalents, and Short-term Investments $60,600,000 USD 5.03%
Accounts Receivable, after Allowance for Credit Loss, Current $254,000 USD -58.9%
Assets, Current $61,801,000 USD 4.16%
Property, Plant and Equipment, Net $666,000 USD -32.9%
Operating Lease, Right-of-Use Asset $764,000 USD -41.4%
Other Assets, Noncurrent $549,000 USD -56.7%
Assets $63,780,000 USD 1.4%
Accounts Payable, Current $2,441,000 USD -47.4%
Employee-related Liabilities, Current $3,142,000 USD 57.7%
Accrued Liabilities, Current $11,539,000 USD 60.8%
Liabilities, Current $14,706,000 USD 17.4%
Operating Lease, Liability, Noncurrent $284,000 USD -71%
Liabilities $14,990,000 USD 11%
Accumulated Other Comprehensive Income (Loss), Net of Tax $50,000 USD -39%
Retained Earnings (Accumulated Deficit) $-422,814,000 USD -13.5%
Stockholders' Equity Attributable to Parent $48,790,000 USD -1.22%
Liabilities and Equity $63,780,000 USD 1.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $-12,794,000 USD -65.3%
Net Cash Provided by (Used in) Financing Activities $107,000 USD
Net Cash Provided by (Used in) Investing Activities $-14,584,000 USD -415%
Common Stock, Shares Authorized 150,000,000 shares 0%
Common Stock, Shares, Issued 67,095,000 shares 37.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $-27,375,000 USD -813%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $10,135,000 USD -22.3%
Deferred Tax Assets, Valuation Allowance $48,434,000 USD 23.6%
Deferred Tax Assets, Gross $48,685,000 USD 23.1%
Operating Lease, Liability $1,523,000 USD -29.1%
Depreciation $89,000 USD -11.9%
Payments to Acquire Property, Plant, and Equipment $80,000 USD 900%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $-50,454,000 USD -18.7%
Lessee, Operating Lease, Liability, to be Paid $1,642,000 USD -31.5%
Property, Plant and Equipment, Gross $5,068,000 USD 0.38%
Operating Lease, Liability, Current $726,000 USD 2.69%
Lessee, Operating Lease, Liability, to be Paid, Year Two $796,000 USD 2.71%
Lessee, Operating Lease, Liability, to be Paid, Year One $710,000 USD 2.75%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $119,000 USD -52.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three $136,000 USD -82.9%
Deferred Tax Assets, Operating Loss Carryforwards $27,374,000 USD 16.8%
Preferred Stock, Shares Authorized 20,000,000 shares 0%
Additional Paid in Capital $471,547,000 USD 11.8%
Depreciation, Depletion and Amortization $93,000 USD -8.82%
Deferred Tax Assets, Net of Valuation Allowance $0 USD
Share-based Payment Arrangement, Expense $5,636,000 USD 26.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares